ONCOBind™ Extracorporeal Procedure for Metastatic Cancer
Disrupting communication across metastatic sites, in cancer, opens the opportunity to think about intervention in a very different way.
Opportunities & Challenges in Metastatic Cancer
“Metastasis is the hallmark of cancer that is responsible for the greatest number of cancer-related deaths.”1 It is estimated that more than 600,000 patients in the United States will die from cancer in 20222, of which 90% will be from metastatic causes.3
Metastatic cancer lacks effective therapies as it is often resistant to chemotherapy, radiation, and immunotherapy. A higher concentration of circulating tumor cells (CTCs) in blood is associated with unfavorable outcomes in metastatic cancer.4
Experimental methods which remove CTCs have been shown to improve outcomes in animals.5 Reduction of CTCs from the bloodstream may provide patient benefit by slowing or preventing metastasis.6
Circulating Tumor Cell Removal Program
ONCOBind Procedure for Circulating Tumor Cell Removal
The ONCOBind Extracorporeal Blood Filter has demonstrated in vitro adsorption of circulating tumor cells (CTCs) from plasma, sparking accelerated clinical research activity in the area of oncology.7
- FDA has approved Investigational Device Exemption (IDE) for clinical study in patients suffering from pancreatic cancer
- Greater than 96% single-pass removal of CTC’s observed in vitro7
- In vitro results replicated at multiple investigational sites
Press Releases
- July 26, 2023
ExThera Medical in Growth Mode after FDA Approval of Investigational Device Exemption - July 13, 2023
ExThera Medical Announces FDA Approval of IDE Application for Use of the ONCOBind Extracorporeal Procedure to Remove Circulating Tumor Cells in Patients with Pancreatic Cancer - Sep 20, 2022
Extracorporeal Blood Filter Removes Circulating Tumor Cells: Dialysis-like Cell Removal Therapy to be Studied for Treating Metastatic Cancer
| 1. | Fares, J., Fares, M.Y., Khachfe, H.H. et al. Molecular principles of metastasis: a hallmark of cancer revisited. Sig Transduct Target Ther 5, 28 (2020). https://doi.org/10.1038/s41392-020-0134-x |
| 2. | https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf |
| 3. | Guan Xiangming, Cancer metastases: Challenges and opportunities, APSB; 5(5)402-18 |
| 4. | https://www.accessdata.fda.gov/cdrh_docs/pdf7/k071729.pdf |
| 5. | Rao SS, Bushnell GG, Azarin SM, Spicer G, Aguado BA, Stoehr JR, Jiang EJ, Backman V, Shea LD, Jeruss JS. Enhanced Survival with Implantable Scaffolds That Capture Metastatic Breast Cancer Cells In Vivo. Cancer Res. 2016 Sep 15;76(18):5209-18. doi: 10.1158/0008-5472.CAN-15-2106 |
| 6. | Rossi E, Fabbri F. CTCs 2020: Great Expectations or Unreasonable Dreams. Cells. 2019 Aug 27;8(9):989. doi: 10.3390/cells8090989. PMID: 31461978; PMCID: PMC6769853. |
| 7. | Koch B, Cinatl JJ, Rothweiler F. Absorption of Circulating Tumor Cells by Hemoperfusion. Poster presented at 13. Jahrestagung der Deutschen Gesellschaft für Nephrologie; September 25, 2021 |
MM0002 Rev A